Clinical Trials Browser

Phase 3 × ruxolitinib × 1 year × Clear all

NCT04562389 2026-04-09

SENTRY

Phase 3 Active not recruiting

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04472598 2026-03-23

TRANSFORM-1

Phase 3 Completed

252 enrolled 17 charts

Neoplasms, Primary Myelofibrosis

NCT04468984 2026-01-09

TRANSFORM-2

Phase 3 Active not recruiting

Neoplasms, Primary Myelofibrosis

NCT04551066 2025-10-21

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Phase 3 Terminated

252 enrolled 18 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04551053 2025-10-02

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Phase 3 Terminated

177 enrolled 15 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Phase 3 Completed

330 enrolled 32 charts 2 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease